JP2012524248A5 - - Google Patents

Download PDF

Info

Publication number
JP2012524248A5
JP2012524248A5 JP2012505138A JP2012505138A JP2012524248A5 JP 2012524248 A5 JP2012524248 A5 JP 2012524248A5 JP 2012505138 A JP2012505138 A JP 2012505138A JP 2012505138 A JP2012505138 A JP 2012505138A JP 2012524248 A5 JP2012524248 A5 JP 2012524248A5
Authority
JP
Japan
Prior art keywords
subject
immunogenic composition
lymphocytes
activated
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012505138A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524248A (ja
JP5661738B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/054743 external-priority patent/WO2010119003A1/en
Publication of JP2012524248A publication Critical patent/JP2012524248A/ja
Publication of JP2012524248A5 publication Critical patent/JP2012524248A5/ja
Application granted granted Critical
Publication of JP5661738B2 publication Critical patent/JP5661738B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012505138A 2009-04-17 2010-04-12 患者をモニターするためのバイオマーカー Expired - Fee Related JP5661738B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09305328.8 2009-04-17
EP09305328 2009-04-17
PCT/EP2010/054743 WO2010119003A1 (en) 2009-04-17 2010-04-12 Biomarker for monitoring patients

Publications (3)

Publication Number Publication Date
JP2012524248A JP2012524248A (ja) 2012-10-11
JP2012524248A5 true JP2012524248A5 (https=) 2013-05-30
JP5661738B2 JP5661738B2 (ja) 2015-01-28

Family

ID=42270292

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012505138A Expired - Fee Related JP5661738B2 (ja) 2009-04-17 2010-04-12 患者をモニターするためのバイオマーカー

Country Status (26)

Country Link
US (2) US20120058493A1 (https=)
EP (1) EP2419728B1 (https=)
JP (1) JP5661738B2 (https=)
KR (1) KR20120027146A (https=)
CN (1) CN102395883B (https=)
AU (1) AU2010237215B2 (https=)
BR (1) BRPI1010512A2 (https=)
CA (1) CA2759050A1 (https=)
CO (1) CO6440591A2 (https=)
CR (1) CR20110513A (https=)
CY (1) CY1114910T1 (https=)
DK (1) DK2419728T3 (https=)
ES (1) ES2445146T3 (https=)
HR (1) HRP20140262T1 (https=)
IL (1) IL214917A (https=)
MX (1) MX2011010920A (https=)
NZ (1) NZ594896A (https=)
PL (1) PL2419728T3 (https=)
PT (1) PT2419728E (https=)
RU (1) RU2555340C2 (https=)
SG (1) SG175060A1 (https=)
SI (1) SI2419728T1 (https=)
SM (1) SMT201400046B (https=)
TW (1) TWI426270B (https=)
WO (1) WO2010119003A1 (https=)
ZA (1) ZA201107545B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013168550A1 (ja) * 2012-05-11 2013-11-14 味の素株式会社 癌免疫療法の評価方法、癌免疫療法評価装置、癌免疫療法評価プログラム、癌免疫療法評価システムおよび情報通信端末装置
US20140244556A1 (en) * 2013-02-27 2014-08-28 Abdul Saleh Methods for and apparatus generating automated pharmaco genetics correlation
US20200353107A1 (en) * 2017-12-08 2020-11-12 Stc.Unm In vivo imaging of tumor infiltration leukocytes
CN114859057A (zh) * 2022-04-13 2022-08-05 江苏省中医院 人结直肠癌或人结直肠癌转移的预测性生物标志物及其应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US6222020B1 (en) 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
FR2632863B2 (fr) 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
DE19520606B4 (de) 1995-06-06 2004-04-08 Roche Diagnostics Gmbh Vorrichtung zur optischen Untersuchung von Oberflächen
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
CA2261989C (en) 1996-07-25 2008-09-30 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
FR2751879B1 (fr) 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
EP1012276A2 (en) 1997-02-24 2000-06-28 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
FR2773885B1 (fr) 1998-01-16 2000-03-03 Elf Antar France Methode de caracterisation de la capacite de neutralisation d'un lubrifiant et dispositif pour la mise en oeuvre de cette methode
JP3119228B2 (ja) 1998-01-20 2000-12-18 日本電気株式会社 液晶表示パネル及びその製造方法
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
CA2362367C (en) 1999-02-04 2004-08-03 Geron Corporation Telomerase reverse transcriptase transcriptional regulatory sequences
EP1155120B1 (fr) 1999-02-22 2006-07-05 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
ES2288488T3 (es) 1999-11-15 2008-01-16 Onyx Pharmaceuticals, Inc. Adenovirus oncoliticos.
AUPQ520800A0 (en) 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
PL212047B1 (pl) 2000-11-23 2012-08-31 Bavarian Nordic As Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
AU2003261252A1 (en) 2002-07-26 2004-02-16 Myomend, Inc. Cardiac rhythm management system with intramural myocardial pacing leads and electrodes
PT2241325E (pt) 2002-10-29 2012-04-12 Coley Pharm Gmbh Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
FR2862648B1 (fr) 2003-11-21 2006-02-03 Biomerieux Sa Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
PL1896051T3 (pl) * 2005-06-28 2015-04-30 Oncothyreon Inc Sposób leczenia pacjentów szczepionką glikoproteiny mucynowej (muc-1)
CA2668942A1 (en) * 2006-12-05 2008-06-12 Transgene S.A. Means and method for raising improved immune response
BRPI0913108A2 (pt) * 2008-05-29 2017-06-20 Trangene S A método ex-vivo para testar se um paciente responderá terapeuticamente a um método de tratamento, uso de níveis de células exterminadores naturais ativadas como um biomarcador, e, kit

Similar Documents

Publication Publication Date Title
Enokida et al. Vaccines for immunoprevention of cancer
KR102723248B1 (ko) 펩타이드 백신
Liu et al. Tollip orchestrates macrophage polarization to alleviate intestinal mucosal inflammation
NZ591137A (en) Methods and systems for predicting response of cells to a therapeutic agent
JP2011509071A5 (https=)
JP2012533322A5 (https=)
BR112013008573A2 (pt) citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer.
Xiao et al. Postoperative tumor treatment strategies: From basic research to clinical therapy
Tian et al. Nanomedicine for combination urologic cancer immunotherapy
Chua et al. Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer
JP2014523920A5 (https=)
Wang et al. Dual‐action psoriasis therapy: antiproliferative and immunomodulatory effects via self‐locking microneedles
JP2012524248A5 (https=)
Pan et al. Gemcitabine resistant triple negative breast tumor derived mesoporous silicon nanovaccine Overcame drug resistance
JP2014521070A5 (https=)
Niu et al. Advances in understanding immune homeostasis in latent tuberculosis infection
NZ621352A (en) Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
RU2011146419A (ru) Биомаркер для мониторинга пациентов
Yan et al. Autophagy enhances antitumor immune responses induced by irradiated hepatocellular carcinoma cells engineered to express hepatitis B virus X protein
JP2010514421A5 (https=)
Sofra et al. A Review of COVID-19 associated factors: CRP, Creatinine, Bilirubin, VLDL, HDL, Triglycerides, Cortisol and Thyroid Function
Fu et al. Heparanase DNA vaccine delivered by electroporation induces humoral immunity and cytoimmunity in animal models
WO2011073905A8 (en) Novel tumor markers
JP2010510495A5 (https=)
Van Loo et al. 5 proffered paper: the life history of 21 breast cancers